Results 271 to 280 of about 66,826 (280)

Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study

Lancet, The, 2018
Robert B M Landewé, Joachim Sieper, Philip J Mease   +2 more
exaly  

Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial

Lancet, The, 2017
D Thaçi, Lisa Weibel, Sandra Philipp
exaly  

Adalimumab

Reactions Weekly, 2010
openaire   +1 more source

Adalimumab

Reactions Weekly, 2022
openaire   +1 more source

Adalimumab

Reactions Weekly, 2018
openaire   +2 more sources

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

New England Journal of Medicine, 2019
Bruce E Sands, Laurent Peyrin-Biroulet, Edward V Loftus   +2 more
exaly  

Adalimumab in Patients with Active Noninfectious Uveitis

New England Journal of Medicine, 2016
Andrew D Dick, Quan Dong Nguyen, Talin Barisani   +2 more
exaly  

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Lancet, The, 2017
Roy M Fleischmann, Robert J Moots, Liza Takiya   +2 more
exaly  

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

New England Journal of Medicine, 2017
Philip J Mease, Oliver Fitzgerald Mb Bch Bao, Mrcpi, Mrcp, Frcpi,, Frcp, Joseph F Merola   +2 more
exaly  

Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial

Lancet, The
exaly